ABSI
Absci Corp
A biotech company that uses artificial intelligence and synthetic biology to design antibodies and other proteins for new medicines. Founded in 2012 by Sean McClain in Vancouver, Washington, the name "Absci" is short for "antibody science." Its platform pairs generative AI with high-throughput lab testing to help drugmakers develop biologic therapies, and it went public through a SPAC merger in 2021.
CUSIP: 00091E109HealthcareUS2 holders
Total Value
$55.77M
Total Shares
19.80M
Net Share Change
+240.8K
Activity
1 buying1 selling
Investor
Value
Shares
Weight
Change
